Clinical Trial Update: A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma. [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on a Phase 1/2 study evaluating Maplirpacept and Glofitamab together in relapsed or refractory diffuse large B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Glofitamab (glofitamab)
• Maplirpacept (PF-07901801)

Snippet

Sponsor: Pfizer | Conditions: Diffuse Large B-Cell Lymphoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING